X
Xiuning Le
Researcher at University of Texas MD Anderson Cancer Center
Publications - 155
Citations - 3788
Xiuning Le is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 86 publications receiving 1862 citations. Previous affiliations of Xiuning Le include University of Texas Health Science Center at San Antonio & Peking Union Medical College.
Papers
More filters
Journal ArticleDOI
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik,E. Felip,Remi Veillon,Hiroshi Sakai,Alexis B. Cortot,Marina Chiara Garassino,J. Mazieres,Santiago Viteri,Hélène Senellart,Jan van Meerbeeck,Jo Raskin,Niels Reinmuth,Pierfranco Conte,Dariusz M. Kowalski,Byoung Chul Cho,Jyoti D. Patel,Leora Horn,Frank Griesinger,Ji Youn Han,Young Chul Kim,Gee Chen Chang,Chen Liang Tsai,James Chih-Hsin Yang,Yuh Min Chen,Egbert F. Smit,Anthonie J. van der Wekken,Terufumi Kato,Dilafruz Juraeva,Christopher Stroh,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,J. Heymach,Xiuning Le +34 more
TL;DR: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients, and adverse events led to permanent discontinuation of tEPotinib in 11% of the patients.
Journal ArticleDOI
Effects of RAS on the genesis of embryonal rhabdomyosarcoma.
David M. Langenau,Matthew D. Keefe,Narie Y. Storer,Jeffrey R. Guyon,Jeffery L. Kutok,Xiuning Le,Wolfram Goessling,Donna Neuberg,Louis M. Kunkel,Leonard I. Zon +9 more
TL;DR: A zebrafish model of RAS-induced ERMS is created, in which animals develop externally visible tumors by 10 d of life, and it is proposed that the zebra fish RMS cancer stem cell shares similar self-renewal programs as those found in activated satellite cells.
Journal ArticleDOI
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.
Xiuning Le,Sonam Puri,Marcelo V. Negrao,Monique B. Nilsson,Jacqulyne P. Robichaux,Theresa A. Boyle,J. Kevin Hicks,Katherine L. Lovinger,Emily Roarty,Waree Rinsurongkawong,Ming Tang,Huiying Sun,Yasir Elamin,Lara Lacerda,Jeff Lewis,Jack A. Roth,Stephen G. Swisher,J. Jack Lee,William N. William,Bonnie S. Glisson,Jianjun Zhang,Vassiliki A. Papadimitrakopoulou,Jhanelle E. Gray,John V. Heymach +23 more
TL;DR: Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients and is associated with diverse, predominantly EGFR-independent genomic alterations.
Journal ArticleDOI
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Tina Cascone,William N. William,Annikka Weissferdt,Cheuk Hong Leung,Heather Lin,Apar Pataer,Myrna C.B. Godoy,Brett W. Carter,Lorenzo Federico,Alexandre Reuben,Abdul Wadud Khan,Hitoshi Dejima,Hitoshi Dejima,Alejandro Francisco-Cruz,Edwin R. Parra,Luisa M. Solis,Junya Fujimoto,Hai T. Tran,Neda Kalhor,Frank V. Fossella,Frank E. Mott,Anne S. Tsao,George R. Blumenschein,Xiuning Le,Jianjun Zhang,Ferdinandos Skoulidis,Jonathan M. Kurie,Mehmet Altan,Charles Lu,Bonnie S. Glisson,Lauren Averett Byers,Yasir Elamin,Reza J. Mehran,David C. Rice,Garrett L. Walsh,Wayne L. Hofstetter,Jack A. Roth,Mara B. Antonoff,Humam Kadara,Cara Haymaker,Chantale Bernatchez,Nadim J. Ajami,Robert R. Jenq,Padmanee Sharma,James P. Allison,Andrew Futreal,Jennifer A. Wargo,Ignacio I. Wistuba,Stephen G. Swisher,J. Jack Lee,Don L. Gibbons,Ara A. Vaporciyan,John V. Heymach,Boris Sepesi +53 more
TL;DR: The results of the phase 2 randomized NEOSTAR trial (NCT03158129) as mentioned in this paper showed that nivolumab + ipilimumab-based therapy enhances pathologic responses, tumor immune infiltrates and immunologic memory, and merits further investigation in operable NSCLC.
Journal ArticleDOI
Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish.
Xiuning Le,David M. Langenau,David M. Langenau,Matthew D. Keefe,Matthew D. Keefe,Jeffery L. Kutok,Donna Neuberg,Leonard I. Zon,Leonard I. Zon +8 more
TL;DR: A heat shock-inducible Cre/Lox-mediated transgenic approach in which activated human kRASG12D can be conditionally induced within transgenic animals by heat shock treatment allowed for the generation of multiple types of RAS-induced tumors and hyperplasia without characterizing tissue-specific promoters.